Difficulty: Medium
Average Score: 88%
Practice
An 83-year-old man is brought to the clinic by his family with complaints stating he can no longer perform his daily activities or be trusted to live on his own. During his neurological exam, he presents with moderate memory loss, apraxia, and anomia. Also, he displays aggressive behaviors throughout the physical exam. He was diagnosed to be in an early stage of Alzheimer's disease. What class of drugs would be most helpful in treating the patient?
Correct answer
B
Rationale
In the case of an 83-year-old man presenting with early-stage Alzheimer's disease characterized by memory loss, apraxia, anomia, and aggressive behaviors, the most appropriate class of drugs for treatment would be cholinesterase inhibitors (Option B). Cholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine, are commonly used in the management of Alzheimer's disease to help improve cognitive function, behavior, and overall quality of life in patients.
Cholinesterase inhibitors work by increasing the levels of acetylcholine in the brain, a neurotransmitter that is depleted in Alzheimer's patients. By inhibiting the enzyme that breaks down acetylcholine, these drugs help to enhance cholinergic neurotransmission, which can lead to improvements in memory, thinking, and behavior.
On the other hand, the other options are not appropriate for treating Alzheimer's disease in this context. Cholinesterase stimulants (Option A) do not exist as a class of drugs; this distractor is misleading. Dopamine agonists (Option C) are used in conditions like Parkinson's disease, not Alzheimer's disease. Muscarinic receptor inhibitors (Option D) would worsen cognitive decline as blocking muscarinic receptors would further reduce acetylcholine levels, exacerbating symptoms.
Educationally, understanding the rationale behind choosing the correct drug class in Alzheimer's disease management is crucial for healthcare professionals, especially those working with older adult populations. It is essential to grasp the pharmacological mechanisms of action of different drug classes to make informed decisions in clinical practice and provide optimal care for patients with neurodegenerative disorders like Alzheimer's disease.
Cholinesterase inhibitors work by increasing the levels of acetylcholine in the brain, a neurotransmitter that is depleted in Alzheimer's patients. By inhibiting the enzyme that breaks down acetylcholine, these drugs help to enhance cholinergic neurotransmission, which can lead to improvements in memory, thinking, and behavior.
On the other hand, the other options are not appropriate for treating Alzheimer's disease in this context. Cholinesterase stimulants (Option A) do not exist as a class of drugs; this distractor is misleading. Dopamine agonists (Option C) are used in conditions like Parkinson's disease, not Alzheimer's disease. Muscarinic receptor inhibitors (Option D) would worsen cognitive decline as blocking muscarinic receptors would further reduce acetylcholine levels, exacerbating symptoms.
Educationally, understanding the rationale behind choosing the correct drug class in Alzheimer's disease management is crucial for healthcare professionals, especially those working with older adult populations. It is essential to grasp the pharmacological mechanisms of action of different drug classes to make informed decisions in clinical practice and provide optimal care for patients with neurodegenerative disorders like Alzheimer's disease.